慢性心力衰竭药物治疗的最新进展

摘要/Abstract

摘要： 心力衰竭患者的死亡率和住院率很高,虽然心衰患者的管理取得了进展,但他们的预后仍然很差。本文综述了慢性心力衰竭药物治疗的最新研究进展,包括药物治疗策略、药物种类、联合治疗和新型药物的研究。以期为临床医生提供有关慢性心力衰竭药物治疗的最新参考。

关键词: 慢性心力衰竭, 药物治疗, 研究进展, 新型药物

翟凤. 慢性心力衰竭药物治疗的最新进展[J]. 心血管病防治知识, 2023, 13(29): 93-96.

[1] Bozkurt B, Coats A, Tsutsui H, et al.Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association[J]. Eur J Heart Fail, 2021,23(3):352-380.
[2] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会,等. 慢性心力衰竭基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(10):936-947.
[3] Ide T, Kaku H, Matsushima S, et al.Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF)[J]. Circ J, 2021,85(9):1438-1450.
[4] Mcmurray J J, Packer M, Desai A S, et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004.
[5] Tsutsui H, Momomura S I, Saito Y, et al.Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction-Results From the PARALLEL-HF Study[J]. Circ J, 2021,85(5):584-594.
[6] Januzzi J L Jr, Prescott M F, Butler J, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction[J]. JAMA, 2019,322(11):1085-1095.
[7] Solomon S D, Mcmurray J, Anand I S, et al.Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J]. N Engl J Med, 2019,381(17):1609-1620.
[8] Solomon S D, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure[J]. Circulation, 2020,141(5):352-361.
[9] Perkovic V, De Zeeuw D, Mahaffey K W, et al.Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials[J]. Lancet Diabetes Endocrinol, 2018,6(9):691-704.
[10] Perkovic V, Jardine M J, Neal B, et al.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J]. N Engl J Med, 2019,380(24):2295-2306.
[11] Wiviott S D, Raz I, Bonaca M P, et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2019,380(4):347-357.
[12] Mcmurray J, Solomon S D, Inzucchi S E, et al.Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019,381(21):1995-2008.
[13] Packer M, Anker S D, Butler J, et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J]. N Engl J Med, 2020,383(15):1413-1424.
[14] Petrie M C, Verma S, Docherty K F, et al.Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes[J]. JAMA, 2020,323(14):1353-1368.
[15] Zannad F, Ferreira J P, Pocock S J, et al.SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J]. Lancet, 2020,396(10254):819-829.
[16] Anker S D, Butler J, Filippatos G, et al.Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J]. N Engl J Med, 2021,385(16):1451-1461.
[17] Butler J, Packer M, Filippatos G, et al.Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction[J]. Eur Heart J, 2022,43(5):416-426.
[18] Griffin M, Rao V S, Ivey-Miranda J, et al.Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects[J]. Circulation, 2020,142(11):1028-1039.
[19] Lytvyn Y, Bjornstad P, Udell J A, et al.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials[J]. Circulation, 2017,136(17):1643-1658.
[20] 廖梦阳, 廖玉华, 余淼,等. SGLT2抑制剂治疗心力衰竭潜在机制的新认识[J]. 临床心血管病杂志,2022,38(1):1-6.
[21] Emdin M, Aimo A, Castiglione V, et al.Targeting Cyclic Guanosine Monophosphate to Treat Heart?Failure: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2020,76(15):1795-1807.
[22] Gheorghiade M, Greene S J, Butler J, et al.Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial[J]. JAMA, 2015,314(21):2251-2262.
[23] Armstrong P W, Pieske B, Anstrom K J, et al.Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2020,382(20):1883-1893.
[24] Ezekowitz J A, Zheng Y, Cohen-Solal A, et al.Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)[J]. Circulation, 2021,144(18):1489-1499.
[25] Heidenreich P A, Bozkurt B, Aguilar D, et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022,145(18):e876-e894.
[26] Malik F I, Hartman J J, Elias K A, et al.Cardiac myosin activation: a potential therapeutic approach for systolic heart failure[J]. Science, 2011,331(6023):1439-1443.
[27] Psotka M A, Gottlieb S S, Francis G S, et al.Cardiac Calcitropes, Myotropes, and?Mitotropes: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2019,73(18):2345-2353.
[28] Teerlink J R, Clarke C P, Saikali K G, et al.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study[J]. Lancet, 2011,378(9792):667-675.
[29] Teerlink J R, Felker G M, Mcmurray J J, et al.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial[J]. Lancet, 2016,388(10062):2895-2903.
[30] WaldenstrOm A, RONQUIST G. Role of exosomes in myocardial remodeling[J]. Circ Res, 2014,114(2):315-324.
[31] Teerlink J R, Diaz R, Felker G M, et al.Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure[J]. N Engl J Med, 2021,384(2):105-116.

慢性心力衰竭药物治疗的最新进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨振. 益气活血法对老年气虚血瘀型失代偿期慢性心力衰竭患者心功能及血清NT-proBNP、CysC的影响[J]. 心血管病防治知识, 2023, 13(9): 28-30.
[2]	罗玉梅. 芪红汤联合芪参益气滴丸治疗冠心病慢性心力衰竭的疗效观察[J]. 心血管病防治知识, 2023, 13(8): 19-21.
[3]	庞建萍, 李少枝, 贺青军. 基于纽曼系统的多学科协作健康教育在慢性心力衰竭患者中的应用[J]. 心血管病防治知识, 2023, 13(8): 49-52.
[4]	刘晓艳. 沙库巴曲缬沙坦治疗扩张型心肌病并慢性心力衰竭患者的研究[J]. 心血管病防治知识, 2023, 13(7): 3-5.
[5]	叶小婷, 吴丽钦, 吕淑贞. 利拉鲁肽联合延续性护理对老年慢性心力衰竭伴糖尿病患者心功能及生活质量的影响研究[J]. 心血管病防治知识, 2023, 13(7): 82-84.
[6]	卢丽华. 心肌收缩力储备联合心脏彩超对高龄慢性心力衰竭患者预后的预测效能研究[J]. 心血管病防治知识, 2023, 13(6): 6-8.
[7]	钟春燕. 慢性心力衰竭患者血清 IL-1β、TNF-α、CTRP5的变化及临床意义[J]. 心血管病防治知识, 2023, 13(5): 21-24.
[8]	柯艳红. 多方位护理干预对慢性心力衰竭患者遵医行为和生活质量的影响[J]. 心血管病防治知识, 2023, 13(4): 51-53.
[9]	范惠琴, 许燕梅, 林金华, 林慧珠. 专项呼吸训练与早期心脏康复干预对老年慢性心力衰竭患者心功能及血压水平的改善分析[J]. 心血管病防治知识, 2023, 13(3): 86-88.
[10]	黄刚, 孙志婷. 基于血清学指标及老年营养风险指数构建心力衰竭患者预后预测模型的研究[J]. 心血管病防治知识, 2023, 13(28): 7-10.
[11]	杨慧锋, 王研, 牛伟华. 老年慢性心力衰竭患者认知功能对自我护理行为影响的研究[J]. 心血管病防治知识, 2023, 13(27): 37-42.
[12]	张淑洁, 毛俊嬛. 冠心病患者抑郁症状影响因素的研究进展[J]. 心血管病防治知识, 2023, 13(26): 92-96.
[13]	柯晓玲, 吴娟娟. 运动康复护理对冠心病慢性心力衰竭患者心功能及运动耐量的影响[J]. 心血管病防治知识, 2023, 13(24): 53-55.
[14]	隋亚玉,孙翠玲. 老年慢性心力衰竭患者接受运动康复治疗的效果及其对心功能指标、机体耐力水平的影响[J]. 心血管病防治知识, 2023, 13(23): 19-21.
[15]	潘启荣, 陆兆华. 难治性高血压的定义演变与最新研究进展[J]. 心血管病防治知识, 2023, 13(2): 94-96.